Healthcare Economist November 5, 2025
Jason Shafrin

That is the question a new paper by Chambers et al. (2025) aims to answer. The authors use data from the Specialty Drug Evidence and Coverage (SPEC) Database, which contains coverage policies related to specialty pharmacy for a large number of US health plans, to examine how n=25 cell and gene therapies are being covered by US commercial health plans. With these data, they find that:

Among 541 indication-plan pair...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

 
Topics: Biotechnology, Insurance, Payer, Pharma / Biotech
H.R.1 Threatens The Stability Of Medicaid Managed Care
WISeR in 2026: Legal, Compliance, and AI Challenges That Could Reshape Prior Authorization for Skin Substitutes
How To Keep Competition Alive In Medicaid Managed Care Markets
Fortifying Medicaid Managed Care for Postpartum Enrollees: The Clearest Path to Improving Maternal Health
UnitedHealth Group's earnings reflect industry-wide pressure

Share Article